BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 31396313)

  • 1. Expression patterns and prognostic value of m
    Liu X; Liu L; Dong Z; Li J; Yu Y; Chen X; Ren F; Cui G; Sun R
    Am J Transl Res; 2019; 11(7):3972-3991. PubMed ID: 31396313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
    Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
    BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression Status And Prognostic Value Of M6A-associated Genes in Gastric Cancer.
    Guan K; Liu X; Li J; Ding Y; Li J; Cui G; Cui X; Sun R
    J Cancer; 2020; 11(10):3027-3040. PubMed ID: 32226518
    [No Abstract]   [Full Text] [Related]  

  • 4. m
    Hou J; Shan H; Zhang Y; Fan Y; Wu B
    Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Alterations of N6-Methyladenosine (m
    Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
    Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methyladenosine-related Genomic Targets are Altered in Breast Cancer Tissue and Associated with Poor Survival.
    Liu L; Liu X; Dong Z; Li J; Yu Y; Chen X; Ren F; Cui G; Sun R
    J Cancer; 2019; 10(22):5447-5459. PubMed ID: 31632489
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer.
    Wang S; Zou X; Chen Y; Cho WC; Zhou X
    Front Genet; 2020; 11():580036. PubMed ID: 33584787
    [No Abstract]   [Full Text] [Related]  

  • 8. N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
    Wu Q; Xie X; Huang Y; Meng S; Li Y; Wang H; Hu Y
    J Cancer; 2021; 12(3):682-692. PubMed ID: 33403026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a m
    Zhao X; Cui L
    Am J Cancer Res; 2019; 9(10):2156-2169. PubMed ID: 31720080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
    Li F; Wang H; Huang H; Zhang L; Wang D; Wan Y
    Front Genet; 2020; 11():994. PubMed ID: 33193582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.
    Xu D; Shao J; Song H; Wang J
    Biomed Res Int; 2020; 2020():9502560. PubMed ID: 32596399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma.
    Li J; Rao B; Yang J; Liu L; Huang M; Liu X; Cui G; Li C; Han Q; Yang H; Cui X; Sun R
    Front Oncol; 2020; 10():769. PubMed ID: 32582536
    [No Abstract]   [Full Text] [Related]  

  • 13. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
    Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ
    Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WTAP activates MAPK signaling through m6A methylation in VEGFA mRNA-mediated by YTHDC1 to promote colorectal cancer development.
    Ye M; Chen J; Yu P; Hu C; Wang B; Bao J; Lu F; Zhong Y; Yan L; Kan J; Bai J; Tian Y; Tang Q
    FASEB J; 2023 Aug; 37(8):e23090. PubMed ID: 37428639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Signature and Identification of Clinical Trait-Related m
    Hou J; Wang Z; Li H; Zhang H; Luo L
    Front Genet; 2020; 11():522. PubMed ID: 32754191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Genetic Alteration Signatures and Prognostic Values of m6A Regulatory Genes in Head and Neck Squamous Cell Carcinoma.
    Zhou X; Han J; Zhen X; Liu Y; Cui Z; Yue Z; Ding L; Xu S
    Front Oncol; 2020; 10():718. PubMed ID: 32547941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma.
    Liang JZ; Liang XL; Zhong LY; Wu CT; Zhang J; Wang Y
    Front Oncol; 2020; 10():617890. PubMed ID: 33732636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microarray and bioinformatic analysis reveal the parental genes of m6A modified circRNAs as novel prognostic signatures in colorectal cancer.
    Liang W; Deng L; Mo C; Chen W; Sha Y; Shi J; Hou X; Zhang Y; Yang M; Ou M
    Front Oncol; 2022; 12():939790. PubMed ID: 35965538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal expression of ABCD3 is an independent prognostic factor for colorectal cancer.
    Zhang Y; Zhang Y; Wang J; Yang J; Yang G
    Oncol Lett; 2020 May; 19(5):3567-3577. PubMed ID: 32269631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer.
    Cao Y; Jiao N; Sun T; Ma Y; Zhang X; Chen H; Hong J; Zhang Y
    Front Cell Dev Biol; 2021; 9():646252. PubMed ID: 33777950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.